Sep 25 2026 10:44 PM EST
AbCellera Shares Rally on ABCL635 Phase‑2 Readout Anticipation and New Partnerships
AbCellera Biologics Inc. (NASDAQ: ABCL) has climbed from roughly $4.05 in May 2026 to about $11.38 by mid‑August, a gain of roughly 181%. The surge coincided with the firm’s advance of its NK3R antagonist, ABCL635, into the Phase 2 portion of a Phase 1/2 trial and the disclosure of two new collaborations that together delivered more than $100 million in upfront cash.
Pipeline catalyst drives share‑price surge
The market’s focus has centered on ABCL635, a NK3R‑targeting antibody for menopausal vasomotor symptoms. Health Canada authorized Phase 1 dosing in early 2026, and Phase 2 enrollment was completed by July. Top‑line efficacy data are slated for the third quarter of 2026, timed with the IMS World Congress on Menopause. Analysts have priced the upcoming readout into their forecasts, lifting the consensus “Strong Buy” rating and pushing average 12‑month price targets to around $17.13, implying upside of 60‑100% from current levels.
Cash infusion from Jazz and Vertex collaborations
In June 2026 AbCellera announced a pre‑clinical research agreement with Jazz Pharmaceuticals that includes an upfront payment of $56 million and the potential for up to $792 million in milestones. A July 2026 deal with Vertex Pharmaceuticals added another $28 million upfront. Together these deals bolstered cash and marketable securities to $567 million as of Q2 2026, with total liquidity exceeding $675 million, enough to fund operations for at least three years.
Financial picture despite revenue dip
Revenue for the quarter ended June 30 2026 fell to $4.05 million, a 49% miss versus consensus estimates of $8.1 million. Net loss widened to $55.4 million (‑$0.18 per share). Nevertheless, the company’s balance sheet remains robust, with zero debt and shareholder equity of $966.9 million at year‑end 2025. The high price‑to‑sales multiple of about 20.1× reflects investor expectations that upcoming milestones will offset the current revenue shortfall.
Sector backdrop and valuation context
The broader antibody‑discovery sector benefits from sustained demand for targeted therapies in oncology, autoimmunity and metabolic disease, and from the integration of AI‑driven discovery platforms—core strengths of AbCellera’s technology. However, rising interest rates and tighter credit conditions have compressed biotech valuations, making the company’s premium multiple more sensitive to forward‑looking catalysts. Analysts, noting the de‑risking of ABCL635 and the cash‑rich balance sheet, have upgraded price targets, but the valuation remains markedly above the industry average of 3.5‑8.8× sales.
Risks and unanswered questions
Key risks include the company’s continued net‑loss trajectory and reliance on partner decisions for milestone payments. The Phase 2 readout for ABCL635 could either validate the therapeutic hypothesis and trigger further upside, or fall short and erode the premium valuation. Competitive pressure from larger biotech firms developing alternative NK3R antagonists adds execution risk. Additionally, macro‑economic headwinds such as higher borrowing costs could affect the cost of capital for future financing rounds.
Investors are therefore weighing a strong cash position and near‑term pipeline catalysts against ongoing losses and the uncertainty of converting partnered programs into revenue. The next quarter’s data releases will be pivotal in determining whether the current share‑price rally can be sustained.